CClinicalTrials.gg
CompletedNCT00389116Updated Feb 25, 2011

Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction

A Phase 4 interventional study of gastrograffin and water in Small Bowel Obstruction, sponsored by University Hospital, Rouen. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-02-25.

Sponsored by University Hospital, Rouen · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Small bowel obstructions are responsible for 2 to 5% of emergency hospital admissions and 20% of all emergency surgical procedures. In 60 to 80% of cases, acute small bowel obstructions are the consequence of intraperitoneal postoperative adhesions. They constitute an extremely frequent pathology, leading to a high rate of hospital admissions and money expense.

Management of small bowel obstruction is based on 2 options: either a surgical approach where all patients are operating on, or a conservative treatment in which surgery is proposed in case of failure of medical treatment. The surgical approach leads to operate on an excessive rate of patients while the medical approach increases the risk of increased small bowel resection, morbidity rate or hospitalization duration.

In order to improve the management of small bowel obstruction, it seems necessary to better distinguish patients that need an emergency surgical procedure from patients in which medical treatment will be useful. Many studies have been performed to investigate the value of imaging in the management of small bowel obstruction, using abdominal X-ray, oral gastrografin administration or CT-Scan.

The aim of this study is to analyse the effect of a systematic performance of imaging investigation on the management of patients presenting with a postoperative small bowel obstruction.

All patients suffering from a postoperative small bowel obstruction will be included in this study. They will be randomised in 2 groups. In group S, patients will have CT-Scan and oral water administration while in group SG, Patients will have CT-Scan and oral gastrografin administration The major end point of this study is to analyse whether imaging examination can reduce the need for a surgical approach or the rate of small bowel resection and to determine its influence on fasting time or hospitalization duration

02

Conditions studied

  • Small Bowel Obstruction
03

In context

Intestinal Obstruction

160 studies on the registry are indexed under Intestinal Obstruction; 27 are open to participants now.

This study's enrollment of 242 is above the median of 80 across 80 interventional studies indexed under Intestinal Obstruction.

Browse Intestinal Obstruction studies →

Lead sponsor

University Hospital, Rouen is the lead sponsor of 410 studies on the registry; 104 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Small bowel obstruction in patients with previous abdominal surgery

Exclusion criteria

Exclusion Criteria:

  • Age less than 18 years
  • Early small bowel obstruction (less than 4 weeks following abdominal surgery)
  • Small bowel obstruction in the course of digestive cancer.
  • Hyperthermic small bowel obstruction
  • Small bowel ischemia (fever, peritoneal signs, increased leucocytosis)
  • Pregnancy ( Elevated béta HCG levels)
  • Inflammatory bowel disease
  • Previous abdominal radiotherapy
  • Pneumoperitoneum
  • Colorectal obstruction
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    1

    Drug: gastrograffin

  • Placebo comparator
    2

    Drug: water

Interventions

  • Druggastrograffin

    ingestion

  • Drugwater

    oral water ingestion

06

What researchers measure

Primary outcomes

  1. Need for surgical management

    Time frame: 2 months

Secondary outcomes

  1. Sensibility and specificity of gastrografin oral administration

    Time frame: 2 months

  2. Sensibility and specificity of CT-Scan.

    Time frame: 2 months

  3. Sensibility and specificity of abdominal X-ray.

    Time frame: 2 months

  4. Fasting time

    Time frame: 2 months

  5. Hospitalization time

    Time frame: 2 months

  6. Number of small bowel resection

    Time frame: 2 months

07

Study locations

1 site
  • CHU
    Rouen, 76000, France
08

References and documents

Publications

  • Cosse C, Regimbeau JM, Fuks D, Mauvais F, Scotte M. Serum procalcitonin for predicting the failure of conservative management and the need for bowel resection in patients with small bowel obstruction. J Am Coll Surg. 2013 May;216(5):997-1004. doi: 10.1016/j.jamcollsurg.2012.12.051. Epub 2013 Mar 19. PubMed 23522439 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00389116
Lead sponsor
University Hospital, Rouen
First posted
Oct 18, 2006
Start date
Nov 2006
Primary completion
Aug 2009
Completion
Aug 2010
Last update
Feb 25, 2011

Study contacts

michel scotté, MD,PhD
principal investigator · CHU Rouen
francois mauvais, MD
study director · chg Beauvais
jean-marc regimbeau, MD, PhD
study director · CHU amiens

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion